Shareholders Approve SeraCare Sale to Private Equity Firm | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences shareholders have approved the $82 million sale of the firm to private equity firm Linden Capital Partners, SeraCare announced today.

Under the terms of the deal, originally announced in February, holders of outstanding shares of SeraCare's common stock will receive $4 per share. The deal is expected to close on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.